Posted by Social Science Research Network REMS: The Next Pharmaceutical Enforcement Priority? – Darren S. Tucker (Bingham McCutchen LLP), Gregory F. Wells (Bingham McCutchen, LLP) and Margaret E. Sheer (Bingham McCutchen, LLP) ABSTRACT: Under the Food and Drug Administration Amendments Act of 2007, the FDA can require the use of risk evaluation and mitigation strategies… Continue reading REMS: The Next Pharmaceutical Enforcement Priority?